Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Affymax, Inc.
NEW YORK, Feb. 25, 2013
NEW YORK, Feb. 25, 2013 /PRNewswire/ -- Attorney Advertising -- Bronstein,
Gewirtz & Grossman, LLC is investigating potential claims on behalf of
purchasers of the securities of Affymax, Inc. ("Affymax" or the "Company")
(Nasdaq: AFFY). The investigation focuses on whether the Company and its
executives violated federal securities laws.
On February 25, 2013, shares of Affymax plummeted over 80% in early morning
trading after the company with Japanese pharmaceutical company Takeda,
announced late Saturday a voluntary recall of anemia drug, Omontys, after a
small percentage of patients experienced serious initial side effects, leading
to a handful of patient deaths. The F.D.A. said in a news release on Sunday
that it had received 19 reports of anaphylaxis, a severe allergic reaction,
and that three of the patients had died, while others required prompt medical
intervention or hospitalization.
If you are aware of any facts relating to this investigation, or purchased
shares of Affymax, you can assist this investigation by contacting either
Peretz Bronstein or Eitan Kimelman of Bronstein, Gewirtz & Grossman, LLC at
212-697-6484 or via email firstname.lastname@example.org. Those who inquire by e-mail are
encouraged to include their mailing address and telephone number.
Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our
primary expertise is the aggressive pursuit of litigation claims on behalf of
our clients. In addition to representing institutions and other investor
plaintiffs in class action security litigation, the firm's expertise includes
general corporate and commercial litigation, as well as securities
arbitration. Attorney advertising. Prior results do not guarantee similar
Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Eitan Kimelman, 212-697-6484
SOURCE Bronstein, Gewirtz & Grossman, LLC
Press spacebar to pause and continue. Press esc to stop.